|
|
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT [[Pegylated interferon alfa-2b]] |
| | IUPAC_name = PEGylated human interferon alpha 2b
| |
| | image =
| |
| | CAS_number = 99210-65-8
| |
| | ATC_prefix = L03
| |
| | ATC_suffix = AB10
| |
| | ATC_supplemental =
| |
| | PubChem =
| |
| | DrugBank = BTD00048
| |
| | C=860 | H=1353 | N=229 | O=255 | S=9
| |
| | molecular_weight = 19269.1 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life = 22-60 hrs
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category =
| |
| | legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| |
| | legal_UK = <!-- GSL / P / POM / CD -->
| |
| | legal_US = <!-- OTC / Rx-only -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| {{CMG}}
| |
| __NOTOC__
| |
| | |
| | |
| ==Overview==
| |
| | |
| '''[[Pegylated]] [[interferon]] alfa-2b''' is a treatment for [[hepatitis C]] developed by Schering-Plough, brand name is Peg Intron.
| |
| | |
| It was approved in January 2001.
| |
| | |
| ==External links==
| |
| * [http://www.fda.gov/cder/biologics/products/pegsche011901.htm"FDA Approval Information"]
| |
| * [http://www.pegintron.com"Peg Intron Website"]
| |
| * [http://news.bbc.co.uk/2/hi/health/6224601.stm "Medicines patent loophole 'found'" at bbc.co.uk]
| |
| | |
| {{Interferons}}
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |